



BRIEF SUMMARY

CONTRAINDICATIONS

There are no known contraindications to the use of sucralfate.

PRECAUTIONS

Duodenal ulcer is a chronic, recurrent disease. While short-term treatment with sucralfate can result in complete healing of the ulcer, a successful course of treatment with sucralfate should not be expected to alter the post-healing frequency or severity of duodenal ulceration.

Drug Interactions: Animal studies have shown that simultaneous administration of CARAFATE (sucralfate) with tetracycline, phenytoin, digoxin, or cimetidine will result in a statistically significant reduction in the bioavailability of these agents. The bioavailability of these agents may be restored simply by separating the administration of these agents from that of CARAFATE by two hours. This interaction appears to be non-systemic in origin, presumably resulting from these agents being bound by CARAFATE in the gastrointestinal tract. The clinical significance of these animal studies is yet to be defined. However, because of the potential of CARAFATE to alter the absorption of some drugs from the gastrointestinal tract, the separate administration of CARAFATE from that of other agents should be considered when alterations in bioavailability are felt to be critical for concomitantly administered drugs.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Chronic oral toxicity studies of 24 months' duration were conducted in mice and rats at doses up to 1 gm/kg (12 times the human dose). There was no evidence of drug-related tumorigenicity. A reproduction study in rats at doses up to 38 times the human dose did not reveal any indication of fertility impairment. Mutagenicity studies were not conducted.

Pregnancy: Teratogenic effects. Pregnancy Category B. Teratogenicity studies have been performed in mice, rats, and rabbits at doses up to 50 times the human dose and have revealed no evidence of harm to the fetus due to sucralfate. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when sucralfate is administered to a nursing woman.

Pediatric Use: Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

Adverse reactions to sucralfate in clinical trials were minor and only rarely led to discontinuation of the drug. In studies involving over 2,500 patients treated with sucralfate, adverse effects were reported in 121 (4.7%).

Constipation was the most frequent complaint (2.2%). Other adverse effects, reported in no more than one of every 350 patients, were diarrhea, nausea, gastric discomfort, indigestion, dry mouth, rash, pruritus, back pain, dizziness, sleepiness, and vertigo.

Issued 8/87

SCREENING MAMMOGRAPHY GUIDELINES

To the Editor:

Dr Steven Taplin, in his editorial on breast cancer screening (*Breast cancer screening: A curious problem in primary care. J Fam Pract 1989; 29:247-248*), never quite gets to the heart of the "curious problem" of physician noncompliance with mammography guidelines. He heads off in the right direction in the next to last paragraph, when he discusses the "ambiguity introduced by indeterminate findings that leave the primary physician with the responsibility of tracking women" and not just tracking but also calming and, finally, reassuring, since the vast majority of these women worry needlessly.

More intense worry comes to those women who have positive findings on mammography but eventual negative biopsies. For every cancer found by screening, anywhere from 5.6¹ to 11² women must live under the cloud until their biopsy results finally come back.

But Wright et al¹ claim the ratio of harm to benefit is even higher. Their reading of the mortality-based studies indicate that cancer detected does not automatically equate to increased survival. For instance, the screening mammogram may not affect outcome in the patients at the two extreme ends of acuity spectrum: indolent cancer in situ vs early metastasis. Discounting for the minimal impact of mammography on survival in these cases, they calculated a harm-benefit ratio as high as 62 biopsies for 1 patient benefited. The authors go on to look at the number of people who need to be screened (as opposed to having a biopsy) to benefit one per-

son. They calculate a ratio as high as 2,041:1. A European critic estimates a ratio of 10,000 women screened to 1 benefited.³

Robin⁴ argues that even some harm comes to those whose primary mammogram is negative; the mere suggestion that screening is needed induces some level of cancer phobia. Barsky⁵ supports the notion that technology has a psychological cost; he points out that although we are objectively healthier, we are worrying more. Result: a net loss in happiness.

The family physician need not consciously know all of the above statistics to become noncompliant. If he has practiced long enough to experience on one hand the relatively low yield of mammography, and on the other hand the anxiety induced by the more frequent false-positives, he may subconsciously put off ordering mammography. Or, if it all comes to consciousness, he may invoke the old saw: first do no harm. Of course, this invocation requires the suppression of the interventionist bias in American medicine⁶; it also means ignoring the growing probability that failure to screen, even in the face of patient refusal, may be grounds for malpractice.⁷

The noncompliant physician may further rationalize his benign neglect by citing cost-effectiveness data.⁸ These sorts of data have no doubt influenced third party payers who continue to drag their feet on reimbursement for screening.^{9,10}

Current standards of care dictate that mammography should be done, particularly in women over 50 years. Of course, primary physicians must commit to the goals of risk reduction set by the larger society. The challenge is to put our professionalism ahead of our "anecdotal" experi-

continued on page 230

Axid[®] (nizatidine capsules) is a trademark of Eli Lilly and Company. Pepcid[®] (Famotidine, MSD) is a trademark of Merck Sharp & Dohme. Tagamet[®] (cimetidine) is a trademark of Smith Kline Beecham. Zantac[®] (ranitidine hydrochloride) is a trademark of Glaxo Pharmaceuticals. Site protective is a trademark of Marion Laboratories, Inc. © 1989, Marion Laboratories, Inc. All rights reserved.



Another patient benefit product from



continued from page 136

ences even though the frequency of detection is low and the costs, both monetary and emotional, often seem high. If primary care physicians believe these costs of screening are too high, they should increase their participation in setting realistic standards. Fortunately, it seems we now have a forum where we can share our unique perspectives: the US Preventive Services Task Force.

*John M. Lee, MD
Merrithew Memorial Hospital
Martinez, and
The Department of Family Practice
University of California,
Davis, California*

References

1. Wright, CJ, et al: Breast cancer screening: A different look at the evidence. *Surgery* 1985; 100:594-598
2. Mitchell H: Organized mammographic screening programmes. *Med J Aust* 1987; 146:89
3. Skrabanek P: The physician's responsibility to the patient. *Lancet* 1988; 1:1155-1157
4. Robin E: *Matters of Life and Death: Risk vs Benefits of Medical Care*. New York. WH Freeman, 1984, p 132
5. Barsky A: The paradox of health. *N Engl J Med* 1988; 318:414-418
6. Payer L: *Medicine and Culture*. New York, Henry Holt, 1987
7. Williams P: Barriers and incentives for primary care physicians in cancer prevention and detection. *Cancer* 1988; 61:2382-2390
8. Eddy DM, Hasselblad V, McGivney W, et al: The value of mammography screening in women under age 50 years. *JAMA* 1988; 259:1512-1519
9. Medicare Mammography Coverage Debated. *Am Med News*, November 27, 1987, p 2
10. Woolhandler, S: Reverse targeting of preventive care due to lack of health insurance. *JAMA* 1988; 259:2872-2874

The preceding letter was referred to Dr Taplin, who responds as follows:

I agree with Dr Lee that I never quite get to the heart of the "curious problem" about the use of mammography, but the reason is simpler than he states. No one knows where the heart of the problem resides.

He has expanded on a point I made and raised important questions about

the risk of mammography (ie, unnecessary biopsies). Whether it influences physicians' use of mammography, however, has not been investigated and is only another intriguing hypothesis. This risk has not been properly highlighted in the rush to promote mammography. How much risk it represents depends not only on the proportion of mammographies that lead to biopsy, but also upon how those biopsies are performed (ie, under local or general anesthesia). The reality that this risk exists needs to be presented to women.

It is clear to me that this risk of mammography is a reason to temper how often we order this procedure, and to whom we offer it, but it should not be a reason to avoid ordering it in women aged 50 years and above. I do not think its routine use in all women 40 to 49 years old is warranted, as I have pointed out elsewhere.¹ The efficacy of mammography in reducing mortality in women aged 50 years and above is clear.^{2,3} The issue now is the optimal interval in this latter age group. An alternative to a single interval in all women has been proposed in the United Kingdom and implemented in at least one HMO in the United States.^{4,5} In this program, breast cancer risk factors are used to vary the interval for screening. The reasoning for varying the interval is to concentrate the use and risks of mammography in women who will most benefit.

Van Der Maas and colleagues⁶ consider these risks and their costs in a recent cost-effectiveness analysis. They conclude that only one third of the screening costs will be compensated by savings in assessment and treatment of early vs late disease, that a 2-year interval appears optimal, and that a 12% reduction in mortality will occur. They point out that such a reduction will result in more lives being saved than currently occurs as a result of cervical cancer screening.

If we would save even the same number of lives as with cervical cancer screening, then the use of mammography seems warranted. I agree with Dr Lee that family physicians should be vocal in setting the stan-

dards for how that will be done, and that the US Preventive Services Task Force is the most reasonable forum.

I would add that we also need to contribute to the fund of knowledge about physician behavior with respect to the use of preventive services. Dr Lee provides a plausible but untested hypothesis about our reluctance to order mammography. The challenge is to test it.

*Stephen Taplin, MD, MPH
Group Health Cooperative of
Puget Sound
Seattle, Washington*

References

1. Taplin S: Controversies in Family Practice. Is screening mammography routinely indicated for women between 40 and 50 years of age? An opposing view. *J Fam Pract* 1988; 27:316-320
2. Shapiro S: Determining the efficacy of breast cancer screening. *Cancer* 1979; 63:1873-1880
3. Tabar L, Fagerberg G, Duffy SW, Day NE: The Swedish two county trial of mammographic screening for breast cancer: Recent results and calculation of benefit. *J Epidemiol Community Health* 1989; 43:107-114
4. Thompson RS, Taplin SH, Carter A, Schnitzer F: Cost effectiveness in program delivery. *Cancer (suppl)* in press
5. Alexander F, Roberst MM, Huggins A, Muir BB: Use of risk factors to allocate schedules for breast cancer screening. *J Epidemiol Community Health* 1988; 42:193-199
6. Van der Maas PJ, de Koning HJ, van Ineveld BM, et al: The cost-effectiveness of breast cancer screening. *Int J Cancer* 1989; 43:1055-1060

DIFFERENTIAL DIAGNOSIS OF VAGINITIS

To the Editor:

I read with interest your recent article by Reed et al.¹ Vaginal yeast infection is a common complaint in women of childbearing age. As discussed in their review, the diagnosis of this infection on clinical or historical grounds alone is unsatisfactory, and confirmation of yeast infection is required. Direct microscopic examination of vaginal smears is notoriously insensitive, and most investiga-

continued on page 232


continued from page 230

BACTROBAN®

(mupirocin)
Ointment 2%
For Dermatologic Use

DESCRIPTION

Each gram of BACTROBAN® Ointment 2% contains 20 mg mupirocin in a bland water miscible ointment base consisting of polyethylene glycol 400 and polyethylene glycol 3350 (polyethylene glycol ointment, N.F.). Mupirocin is a naturally-occurring antibiotic. The chemical name is 9-4-(5S)-(2S,3S-epoxy-5S-hydroxy-4S-methylhexyl)-3R,4R-dihydroxytetrahydropyran-2S-yl)-3-methylbut-2(E)-enoxyloxy-nonanoic acid. The chemical structure is:

**CLINICAL PHARMACOLOGY**

Mupirocin is produced by fermentation of the organism *Pseudomonas fluorescens*. Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl transfer-RNA synthetase. Due to this mode of action, mupirocin shows no cross resistance with chloramphenicol, erythromycin, fusidic acid, gentamicin, lincomycin, methicillin, neomycin, novobiocin, penicillin, streptomycin, and tetracycline.

Application of ¹⁴C-labeled mupirocin ointment to the lower arm of normal male subjects followed by occlusion for 24 hours showed no measurable systemic absorption (<1.1 nanogram mupirocin per milliliter of whole blood). Measurable radioactivity was present in the stratum corneum of these subjects 72 hours after application.

Microbiology: The following bacteria are susceptible to the action of mupirocin *in vitro*: the aerobic isolates of *Staphylococcus aureus* (including methicillin-resistant and β-lactamase producing strains), *Staphylococcus epidermidis*, *Staphylococcus saprophyticus*, and *Streptococcus pyogenes*.

Only the organisms listed in the **INDICATIONS AND USAGE** section have been shown to be clinically susceptible to mupirocin.

INDICATIONS AND USAGE

BACTROBAN® (mupirocin) Ointment is indicated for the topical treatment of impetigo due to: *Staphylococcus aureus*, beta hemolytic *Streptococcus**, and *Streptococcus pyogenes*.

*Efficacy for this organism in this organ system was studied in fewer than ten infections.

CONTRAINDICATIONS

This drug is contraindicated in individuals with a history of sensitivity reactions to any of its components.

WARNINGS

BACTROBAN® Ointment is not for ophthalmic use.

PRECAUTIONS

If a reaction suggesting sensitivity or chemical irritation should occur with the use of BACTROBAN® Ointment, treatment should be discontinued and appropriate alternative therapy for the infection instituted.

As with other antibacterial products prolonged use may result in overgrowth of non-susceptible organisms, including fungi.

Pregnancy category B: Reproduction studies have been performed in rats and rabbits at systemic doses, i.e., orally, subcutaneously, and intramuscularly, up to 100 times the human topical dose and have revealed no evidence of impaired fertility or harm to the fetus due to mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing mothers: It is not known whether BACTROBAN® is present in breast milk. Nursing should be temporarily discontinued while using BACTROBAN®.

ADVERSE REACTIONS

The following local adverse reactions have been reported in connection with the use of BACTROBAN® Ointment: burning, stinging, or pain in 1.5% of patients; itching in 1% of patients; rash, nausea, erythema, dry skin, tenderness, swelling, contact dermatitis, and increased exudate in less than 1% of patients.

DOSAGE AND ADMINISTRATION

A small amount of BACTROBAN® Ointment should be applied to the affected area three times daily. The area treated may be covered with a gauze dressing if desired. Patients not showing a clinical response within 3 to 5 days should be re-evaluated.

HOW SUPPLIED

BACTROBAN® (mupirocin) Ointment 2% is supplied in 15 gram tubes.
(NDC #0029-1525-22)

Store between 15° and 30°C (59° and 86°F).

0938020/688-REV. FEB. 1988

Reference:

1. Data on file, Medical Department, Beecham Laboratories.

Beecham
laboratories
BRISTOL, TENNESSEE 37620

tions report a correlation of only 36% to 45% with candidosis.²⁻⁴ Culture methods are unable to differentiate commensal from pathogenic yeasts, and whereas the sensitivity of this method is high, positive predictive values of only 36% to 46% have been reported.^{3,5} The new latex particle agglutination (LPA) test mentioned in the article of Reed et al¹ has been widely evaluated and has been found to have both high positive predictive values (76% to 100%)^{2,3,6} and high sensitivity. We found the sensitivity of this test for the presence of *Candida albicans* to be greater than 65%⁵ (not 36% as quoted in the article), which compares with sensitivities of 72% to 81% reported in other studies.^{2,3,6} A positive correlation was observed between signs and symptoms of infection and yeast load. The likelihood of a positive reaction with the LPA test also increased with the number of yeasts present in the vagina; thus the test was able to differentiate true infection from women harboring commensal yeasts. In our hands the LPA test proved to be a satisfactory alternative for the diagnosis of vaginal candidosis and was able to yield rapid results, within 2 to 3 minutes, an important consideration for an in-office test.

V. Hopwood, PhD

Regional Mycology Laboratory
General Infirmary at Leeds
Leeds, UK

References

1. Reed BD, Huck W, Zavone P: Differentiation of *Gardnerella vaginalis*, *Candida albicans*, and *Trichomonas vaginalis* infections of the vagina. *J Fam Pract* 1989; 28:673-680
2. Rajakumar R, Lacey CJN, Evans EGV, Carney JA: Use of slide latex agglutination test for rapid diagnosis of vaginal candidosis. *Genitourin Med* 1987; 63:192-195
3. Evans EGV, Lacey CJN, Carney JA: Criteria for the diagnosis of vaginal candidosis: Evaluation of a new latex agglutination test. *Eur J Obstet Gynecol Reprod Biol* 1986; 22:365-371
4. Gough PM, Warnock DW, Turner A, et al: Candidosis of the genital tract in non-pregnant women. *Eur J Obstet Gynecol Reprod Biol* 1985; 19:237-246
5. Hopwood V, Warnock DW, Milne JD, et al:

- Evaluation of a new slide latex agglutination test for diagnosis of vaginal candidosis. *Eur J Clin Microbiol* 1987; 6:392-394
6. Hopwood V, Evans EGV, Carney JA: Rapid diagnosis of vaginal candidosis by latex particle agglutination. *J Clin Pathol* 1985; 38:455-458

The preceding letter was referred to Dr Reed, who responds as follows:

The above letter by V. Hopwood reiterates the findings that the in-office diagnosis of *Candida* vulvovaginitis based on clinical findings and potassium hydroxide slide preparations has been notoriously inexact, as reflected in our study¹ and others. The search for improved methods for making the rapid diagnosis of *Candida* vulvovaginitis in the office setting is an important one if this inaccuracy is to be lessened.

The sensitivity of the slide latex agglutination test (SLA) as quoted in our paper reflected the comparison of this test with that of culture in all patients evaluated by Hopwood et al in their study.² The 65.2% sensitivity of the test, as quoted by Hopwood, indicates the comparison of the test with culture in patients meeting specific clinical criteria and having a positive culture or microscopic slide test. This discrepancy between these sensitivities exists because the slide test is more likely to be positive in those with large numbers of organisms present than in those with fewer organisms. The association between specific clinical symptoms (such as pruritus) and the numbers of organisms present has been similarly reported by Odds et al,³ although similar associations between numbers of organisms and other symptoms and signs have not been consistent. A test such as this that may selectively identify those patients with greater numbers of *Candida* organisms may therefore be useful in clinical practice. Further research is needed to confirm that the patients identified by this test are actually those who benefit from treatment, and that those with smaller numbers of organisms who are only identified by culture do not eventually require treatment as well.

Pending further studies, the use of these in-office tests in the diagnosis of vaginitis may improve the diagnostic accuracy in many cases. When symptoms recur or persist, evaluation by culture would still be recommended.

Barbara D. Reed, MD, MSPH
 Department of Family Practice
 University of Michigan
 School of Medicine
 Ann Arbor

References

1. Reed BD, Huck W, Zazove P: Differentiation of *Gardnerella vaginalis*, *Candida albicans*, and *Trichomonas vaginalis* infections of the vagina. *J Fam Pract* 1989; 28:673-680
2. Hopwood V, Warnock DW, Milne JD et al: Evaluation of a new slide latex agglutination test for diagnosis of vaginal candidosis. *Eur J Clin Microbiol* 1987; 6:392-394
3. Odds FC, Webster CE, Mayuranathan P, Simmons PD: *Candida* concentrations in the vagina and their association with signs and symptoms of vaginal candidosis. *J Med Vet Mycol* 1988; 26:277-283

DECISION AND COST-EFFECTIVENESS ANALYSIS

To the Editor:

I was quite interested to see the presentation of a formal decision analysis in "Screening for Asymptomatic Bacteriuria in Pregnancy" (Wadland WC, Plante DA. *J Fam Pract* 1989; 29:372-376). Decision analysis is a very useful tool if used properly, and many "traditional" management strategies in family medicine need to be reassessed using this technique.

While I congratulate Wadland and Plante for the thoroughness of their model, I would like to point out some potential errors incorporated into their particular decision analysis. First, the estimation of the combined sensitivity and specificity of the mini-culture dip slide is not in concordance with accepted methods. The dip slide tests two independent etiologies for bacteriuria, and if either paddle is positive, bacteriuria is said to be present. Therefore, this is an applica-




Figure 1. Decision tree modeling the choices between screening and not screening women for asymptomatic bacteriuria. BU denotes bacteriuria.

tion of parallel testing using a disjunctive positivity criterion, which has been shown by Cebul et al¹ to yield a combined sensitivity (where T1 is test 1 and T2 is test 2) of: (sensitivity of T1) + [1 - (sensitivity of T1)]*(sensitivity of T2). The combined specificity of T1 and T2 is: (specificity of T1)*(specificity of T2). Using this method, the combined sensitivity of the two paddles of the dip slide is 1.00; the specificity is 0.321.

Reconstructing the decision tree using these data and Bayes' theorem, some significant changes in the probabilities of several branches of the Screen option result (see Figure 1).

Second, it is stated that the CLED panel of the dip slide identifies 5% of the pathogens responsible for urinary tract infections. In point 2 of the charge assumptions, the authors assume that 5% of positive dip slides will come from this CLED panel.

continued on page 236

INDAPAMIDE 2.5mg

Brief Summary

DESCRIPTION: Lozol® (indapamide) is an oral antihypertensive/diuretic.
INDICATIONS AND USAGE: Lozol is indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs.
 Lozol is also indicated for the treatment of salt and fluid retention associated with congestive heart failure.
Usage in Pregnancy: See PRECAUTIONS.
CONTRAINDICATIONS: Anuria. Known hypersensitivity to indapamide or to other sulfonamide-derived drugs.
WARNINGS: Hypokalemia occurs commonly with diuretics, and electrolyte monitoring is essential, particularly in patients with hypokalemia. Warning signs include dry mouth, thirst, weakness, fatigue, lethargy, drowsiness, restlessness, muscle pains or cramps, hypotension, oliguria, tachycardia, and gastrointestinal disturbance. Electrolyte determinations are particularly important in patients who are vomiting excessively or receiving parenteral fluids, in patients subject to electrolyte imbalance (including those with heart failure, kidney disease, and cirrhosis), and in patients on a salt-restricted diet.
 In general, diuretics should not be given concomitantly with lithium because they reduce its renal clearance and add a high risk of lithium toxicity. Read prescribing information for lithium preparations before use of such concomitant therapy.
PRECAUTIONS: General
 1. **Hypokalemia and Other Fluid and Electrolyte Imbalances:** Periodic determinations of serum electrolytes should be performed at appropriate intervals. In addition, patients should be observed for clinical signs of fluid or electrolyte imbalance, such as thirst, weakness, fatigue, lethargy, drowsiness, restlessness, muscle pains or cramps, hypotension, oliguria, tachycardia, and gastrointestinal disturbance. Electrolyte determinations are particularly important in patients who are vomiting excessively or receiving parenteral fluids, in patients subject to electrolyte imbalance (including those with heart failure, kidney disease, and cirrhosis), and in patients on a salt-restricted diet.
 The risk of hypokalemia secondary to diuresis and natriuresis is increased when larger doses of water rather than administration of salt, except in rare instances when the concomitant use of corticosteroids or ACTH. Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Hypokalemia can sensitize or exaggerate the response of the heart to the toxic effects of digitalis, such as increased ventricular irritability.
 Dilutional hyponatremia may occur in edematous patients; the appropriate treatment is restriction of water rather than administration of salt, except in rare instances when the hyponatremia is life threatening. However, in actual salt depletion, appropriate replacement is the treatment of choice. Any chloride deficit that may occur during treatment is generally mild and usually does not require specific treatment except in extraordinary circumstances as in liver or renal disease.
 2. **Hypertension and Gout:** Serum concentrations of uric acid increased by an average of 1 mg/100 mL in patients with indapamide. In patients with a history of gout precipitated in certain patients receiving indapamide (see ADVERSE REACTIONS below). Serum concentrations of uric acid should therefore be monitored periodically during treatment.
 3. **Renal Impairment:** Indapamide, like the thiazides, should be used with caution in patients with severe renal disease, as reduced plasma volume may exacerbate or precipitate azotemia. If progressive azotemia develops, patients receiving indapamide, withholding or discontinuing diuretic therapy should be considered. Renal function tests should be performed periodically during treatment with indapamide.
 4. **Impaired Hepatic Function:** Indapamide, like the thiazides, should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.
 5. **Glucose Tolerance:** Latent diabetes may become manifest and insulin requirements generally mild and usually does not require specific treatment except in extraordinary circumstances as in liver or renal disease.
 6. **Calcium Excretion:** Calcium excretion is decreased by diuretics pharmacologically related to indapamide. In long-term studies of hypertensive patients, however, serum concentrations of calcium increased only slightly with indapamide. Prolonged treatment with drugs pharmacologically related to indapamide may in rare instances be associated with hypocalcemia and hypoparathyroidism, such as hypocalcemia, hypoparathyroidism, and hypocalcemic tetany. Treatment should be discontinued before tests for parathyroid function are performed. Like the thiazides, indapamide may decrease serum PBI levels without signs of thyroid disturbance.
 7. **Interaction With Systemic Lupus Erythematosus:** Thiazides have exacerbated or activated systemic lupus erythematosus and this possibility should be considered with indapamide as well.
DRUG INTERACTIONS:
 1. **Other Antihypertensives:** Lozol (indapamide) may add to or alter the action of other antihypertensives. In uncontrolled trials that compared the effect of indapamide combined with other antihypertensive drugs with the effect of the other drugs administered alone, there was no notable change in the nature or frequency of adverse reactions associated with the combined therapy.
 2. **Lithium:** See WARNINGS.
 3. **Post-Sympathectomy Patient:** The antihypertensive effect of the drug may be diminished in the post-sympathectomy patient.
 4. **Norepinephrine:** Indapamide, like the thiazides, may decrease arterial responsiveness to norepinephrine, thus its diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.
CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: Both mouse and rat life-time carcinogenicity studies were conducted. There was no significant difference in the incidence of tumors between indapamide-treated and the control groups.
Pregnancy/ Teratogenic Effects: Pregnancy Category B. Reproduction studies have been performed in rats, mice and rabbits at doses up to 6,250 times the therapeutic human dose and have revealed no evidence of impaired fertility or harm to the fetus due to indapamide. Postnatal development in rats was unaffected by administration of parent animals during gestation. There are, however, no adequate and well-controlled studies in pregnant women. Moreover, hypokalemia is known to cross the placental barrier and appear in cord blood. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. There may be hazards associated with the use of such drugs during pregnancy, such as thrombocytopenia, and possibly other adverse reactions that have occurred in the adult.
Nursing Mothers: It is not known whether this drug is excreted in human milk. Because most drugs are excreted in human milk, if use of this drug is deemed essential, the patient should stop nursing.
ADVERSE REACTIONS: Most adverse effects have been mild and transient. In long-term controlled clinical studies, cumulative adverse reactions—5% are headache, dizziness, fatigue, weakness, loss of energy, lethargy, tiredness or malaise, muscle cramps or spasms, or numbness of the extremities, nervousness, tension, anxiety, irritability, or agitation. Cumulative adverse reactions—5% are light-headedness, drowsiness, vertigo, insomnia, depression, blurred vision, constipation, nausea, vomiting, diarrhea, gastric irritation, abdominal pain or cramps, anorexia, orthostatic hypotension, premature ventricular contractions, irregular heart beat, palpitations, frequency of urination, nocturia, polyuria, rash, hives, pruritus, vasculitis, impotence or reduced fluid, rhinorrhea, flushing, hyperkalemia, hyperglycemia, hyponatremia, hypochloremia, increase in serum urea nitrogen (BUN) or creatinine, glycosuria, weight loss, dry mouth, tingling of extremities.
 Clinical hypokalemia (i.e., lowered serum potassium concentration with concomitant clinical signs or symptoms) occurred in 3% and 7% of the patients given indapamide 2.5 mg and 5.0 mg, respectively, in a long-term study of both doses; 157 patients given indapamide, potassium supplementation was given to 12% of patients on indapamide 2.5 mg and 27% of patients on indapamide 5.0 mg.
 Other adverse reactions reported with antihypertensive/diuretics are jaundice (intrahepatic cholestatic jaundice), sialadenitis, xanthopsia, photosensitivity, purpura, necrotizing angitis, fever, respiratory distress (including pneumonitis), and anaphylactic reactions, also, agranulocytosis, leukopenia, thrombocytopenia, and aplastic anemia. These reactions should be considered as possible occurrences with clinical usage of Lozol.
HOW SUPPLIED: Lozol (indapamide). White, round film-coated tablets of 2.5 mg in bottles of 100 (NDC 0075-0082-00), 1,000 (NDC 0075-0082-99), and in unit-dose blister packs; boxes of 100 (10 x 10) (NDC 0075-0082-92).
CAUTION: Federal (U.S.A.) law prohibits dispensing without prescription.
 Keep tightly closed. Store at room temperature; avoid excessive heat. Dispense in tight containers as defined in USP.
 See product circular for full prescribing information. Revised: November 1988 (AS)

References: 1. Weidmann P, Gerber A: Effects of treatment with diuretics on serum lipoproteins. *J Cardiovasc Pharmacol* 1984;6(suppl):260-268. 2. Meyer-Sabellek W, Gotzler N, Heitz J, et al: Serum lipoprotein levels during long-term treatment of hypertension with indapamide. *Hypertension* 1985;7(suppl 2):170-174. 3. Belling S, Vukovich RA, Neiss ES, et al: Long-term experience with indapamide. *Am Heart J* 1983;106:258-262. 4. Scalabrino A, Galeone F, Giuntoli F, et al: Clinical investigation on long-term effects of indapamide in patients with essential hypertension. *Curr Ther Res* 1984;35:17-22.

See product circular for full prescribing information.
 Product of Servier Research Institute

RORER PHARMACEUTICALS
 a division of
RORER PHARMACEUTICAL CORPORATION
 Fort Washington, PA U.S.A. 19034
 © 1989 Rorer Pharmaceutical Corporation

LOZ06189A 1/89 FC#89-91 Printed in U.S.A.

LETTERS TO THE EDITOR

continued from page 233

This assumption does not logically follow from the first statement, since urine specimens with 5% of all pathogenic species may not be the same as 5% of all urine samples with pathogenic bacteria in them.

A third point has to do with the somewhat unusual presentation of the end-point values of the decision tree as "weighted branch charges." The authors presented these charges as already "averaged out" for 100 patients presenting, instead of the usual method of showing the actual charges for a given patient ending up at that end-point, as one would do prior to "averaging out" the tree. This slight departure from "standard" presentation has no effect on the final analysis.

If the model is reconstructed to include the revisions mentioned above, we find that of 100 patients presenting, if we do not screen for asymptomatic bacteriuria, 3.5 cases of pyelonephritis would be expected. If we do screen, only 1.5 cases of pyelonephritis should be expected. As might be anticipated, not screening costs less than screening, but the cost of screening amounts to only about \$486 per case of pyelonephritis prevented, subject to the authors' baseline assumptions.

I believe that decision analysis and cost-effectiveness analysis are powerful and important tools with significant applications in family medicine. However, the possibility of faulty assumptions or methods becomes significant with these complex models, and we must take extreme care in our formulations if we expect these analyses to be credible.

Daniel S. Marley, MD
 Clinical Decision Making Program
 Department of Family Medicine
 University of Oklahoma
 Oklahoma City

Reference

1. Cebul RD, Hershey JC, Williams SV: Using multiple tests: Series and parallel approaches. *Clin Lab Med* 1982; 2:871-890

The preceding letter was referred to Drs Wadland and Plante, who respond as follows:

We appreciate the thoughtful comments by Dr Marley. With respect to his first two points, the following replies about parallel testing are in order. The formulae he cited are correctly applied to two independent tests which are used to diagnose the same disease. However, we assumed that there are two separate etiologies for asymptomatic bacteriuria, in essence two separate diseases. In 95% of the cases the true disease is potentially identified by the MacConkey paddle. In the remaining 5% of cases the true disease is potentially identified by the CLED paddle. We assumed the paddles to be independent tests and that only one "disease" or cause for bacteriuria could exist at any one time. For these reasons, we feel that the weighted sensitivity and specificity values used in the model are valid.

With respect to the last point, the actual computer model generated cost data as suggested by Dr Marley. For example, the actual unweighted cost of the top branch for a single patient is \$3672. The costs column at the right of the decision tree were "weighted" for illustrative purposes only and are similar in concept to "risk profiles."

William C. Wadland, MD
 Department of Family Practice
 Dennis A. Plante, MD
 Department of Medicine
 University of Vermont
 Burlington

COSTS OF ELECTRONIC INFORMATION SERVICES

To the Editor:

The October *American Family Physician* announces that "The AAFP recently unveiled an online electronic information service that will be carried on AMA/NET." This excites and disturbs me. It is good to see the American Academy of Family Physicians' concern, but the link to AMA/NET is questionable. This be-

came apparent to me at the annual SCAMC (Symposium on Computer Applications in Medical Care) conference in Washington, DC, November 5-8, 1989.

At SCAMC I attended the panel on "Identifying and Meeting Physician Information Needs." Dr William Yasnoff of AMA/NET, Dr Edward J. Huth, prestigious writer from the American College of Physicians, Dr Brian Haynes, acclaimed internist of Canada, and Patricia Ryan of Paper-Chase were on the panel. Among these giants, family practice needs became lost. There was one family physician, but he was not on the official panel. Dr Huth wrote the equation $value = utility/cost$, and then Dr Yasnoff directed the discussion to focus on why AMA/NET was not being used.

The American Medical Association is pushing AMA/NET to increase its membership, not to serve the information needs of family physicians. As a family physician who first trained as a medical librarian online searcher, I use GRATEFUL MED and DIALOG. They meet my information needs for about \$50 per year plus online time. GRATEFUL MED is easy to access and inexpensive. It is my primary information resource. DIALOG, the oldest and largest commercial online service, provides me with more drug databases, business files, newspaper files, government document files, and other medical files than AMA/NET. I do not want to join the AMA to obtain the lower rate AMA members enjoy to search AMA/NET to find out about the AAFP. The subscription fee for using AMA/NET is \$160 a year for nonmembers plus about \$16 an hour of online time. Even with the occasional user plan of \$75 per year, AMA/NET is still more expensive for less content than what I already have.

An electronic information service

is a dynamic outreach for the AAFP, but why through the AMA? An AAFP electronic bulletin board would have cost less than AAFP's venture with AMA. Family practice departments could easily use their university's BITNET for such a communication service.

Cathy L. Schell, MD, MLS
Cutler Army Hospital,
Ft Devens, Mass

PRIMARY CARE: READY FOR MERGER?

To the Editor:

There is only one important question regarding the proposal to merge family medicine with the other primary care disciplines.^{1,2} Will combining the primary care specialties increase their collective political clout so that the important issues can be dealt with more effectively? Considering our different vested interests, I doubt it. By itself, a merger does not even partially resolve any substantive problems.

One such problem is that the downward trend in student interest has continued unabated in spite of the stepped-up marketing of the different programs. A merger—particularly one that expands training by 1 year—will not make primary care more attractive to students. Only fundamental changes, such as reimbursement reform or quotas for residency training positions, will alter the current primary care-specialist ratio of trainees.

Another major issue is the gatekeeper's role in cost containment. Primary care physicians are put in the untenable position of having all of the responsibility and none of the authority for controlling medical costs. Expensive advances in technology, defensive medicine fostered by mal-

practice litigation, and patient expectation of specialty referral on demand are largely beyond the control of the primary care provider. If cost containment is going to work, fundamental changes in the medical system and in public expectations are needed to empower gatekeepers.

Perhaps the greatest problem facing American medicine is access to medical care. Basic health care is looked at as a right of the American people, yet there is confusion as to what that right is and how it can be secured. Americans have the right to health care only if they can pay for it or if they can somehow work through the patchwork maze of public health care. Because employer-sponsored insurance is not uniform and because eligibility guidelines for entitlement programs are ridiculously low, the number of patients not covered by either grows daily.

I agree that it is logical to work for an eventual merging of the primary care disciplines, but logic does not seem to be the driving force in medicine today. Before embarking on this fundamental change in primary care education, we should wait until we evolve into a more rational, humane health care system. For now, let us leave this minor issue and focus on the real problems facing us.

Bill Hensel, MD
Family Practice Center
The Moses H. Cone
Memorial Hospital
Greensboro, North Carolina

References

1. Perkoff GT: Should there be a merger to a single primary care specialty for the 21st century? An affirmative view. *J Fam Pract* 1989; 29:185-188
2. Scherger JE: Should there be a merger to a single primary care specialty for the 21st century? An opposing view. *J Fam Pract* 1989; 29:189-190